High-level scientists & high-end laboratory equipment for the most relevant in vitro CNS/PNS studies

High-level scientists & high-end laboratory equipment for the most relevant in vitro CNS/PNS studies

Neuro-Sys is an innovative French Drug Discovery and Services company focusing on neurodegenerative diseases, such as :

Alzheimer’s disease (AD)
Parkinson’s disease (PD)
Huntington’s disease (HD)
Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease)
Multiple Sclerosis (MS)
Peripheral Neuropathies

Neuro-Sys has developed specific preclinical models of neurological diseases to accurately determine the pharmacological profiling of lead compounds and explore their underlying mechanism of action. All processes are standardized and automated.

Neuro-Sys also develops its own drug discovery programs based on an innovative and unique approach.

With the support of its team of neuroscientists, pharmacists and its high level scientific board, Neuro-Sys is the partner of choice to provide innovative and promising active new compounds and preclinical services to the pharmaceutical, nutraceutical, and biotech industries.

Scientific board

Poindron, PharmD, PhD.
Chairman of the Board.

Pr. Poindron, Professor of Virology and Cell Biology at The Université de Strasbourg (formerly Université Louis Pasteur), has been one of the BioValley initiative promoters with Swiss and German colleagues. He has specifically worked on interferon, adoptive immunotherapy of cancer and neurodegenerative diseases, using modelled mixed cell cultures.

Anton, PhD.

Emeritus of the University of Strasbourg (France), Pr. Robert ANTON is a member of the national Academies of Medicine and Pharmacy and former member of the High Council of Public Health at the Ministry of Health in Paris. Specialized in the field of natural products, he has been a member of several European panels and Committees of experts concerning drugs, cosmetics and food supplements. For example, he has been an expert at the ANSM (French Agency of Drug Safety), at the European Commission of Pharmacopoeia, but also Chairman at the Public Health Committee at the Council of Europe, at the SCCNFP (Scientific Committee on Cosmetics and Non Food Products) in Brussels and still is an expert at EFSA (European Food Safety Authority).

Chemat, PhD.

Pr. Chemat, Professor of Chemistry at Avignon University (France), is Director of GREEN Extraction Team (alternative extraction techniques and solvents), co-director of ORTESA LabCom research unit Naturex-UAPV, and scientific coordinator of PEEV (Industrial platform for green extraction at Valréas). His main research interests are focused on innovative and sustainable extraction techniques, protocols and solvents (especially microwave, ultrasound and bio-based solvents) for food, pharmaceutical, fine chemistry, biofuel, and cosmetic applications.

Mariani, MD, PhD.

Pr. Mariani, Professor of Cell Biology and Biology of aging at the University Pierre & Marie Curie (UPMC) is also practicing at the Charles Foix Hospital (Public Assistance-Paris Hospitals, AP-HP). Since its establishment in 2001, he has run the Neurobiology of Adaptive Processes Laboratory (CNRS/UPMC) which conducts research concerning the nervous system’s late stages of development, its ageing and some of its neurodegenerative pathologies.

Mottier, PharmD.

Pharmacist and MSc in formulation, process and production with 15 years in CMC (Chemistry, Manufacturing and Controls) development for the pharmaceutical industry. Has worked for all sizes and types of companies from a small virtual company to a big pharma and CDMO publicly or privately owned, as well as CMC expert consultancy. Experience in the sourcing or synthesis of numerous drug substances and development of a wide variety of formulations for projects in all stages of development. Has worked on numerous CMC sections for European, American and Asian regulatory bodies.

Ollivier, PhD.

Pr. Ollivier, Professor of Pharmacognosy, Phytochemistry, Phytotherapy and Etnopharmacology, is specialized in the discovery of bioactive molecules from plant biodiversity. She is a member of the Society of Medicinal Plant Research, and the Association Française pour l’Enseignement et la Recherche en Pharmacognosie (AFERP) as well as the vice president of the French Society of Enthnopharmacology.

Stoclet, PharmD, PhD.

Pr. Stoclet, former professor of pharmacology at the Faculty of Pharmacy of Strasbourg, is an honorary member of the Académie Nationale de Pharmacie, a member of the French Pharmacology Society, the British Pharmacology Society and the American Pharmacology and Experimental Therapeutics Society.

Loeffler, PhD.

Dr Loeffler is a Research Director at INSERM, U1118 located at the Faculty of Medicine of Strasbourg. Dr Loeffler is studying the molecular mechanisms of neurodegenerative diseases, and particularly the metabolic and neuronal dysfunctions underlying the clinical spectrum extending from amyotrophic lateral sclerosis and fronto-temporal dementia.

Collaboration and partners

Strategic alliances have been setup with significant companies and institutions across the world to provide the most narrowly-targeted services and screening assays compliant with specific client needs.

Financial partners: